Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merger augurs "new era" in UK cancer research:

This article was originally published in Clinica

Executive Summary

The UK leading cancer charities Cancer Research Campaign and Imperial Cancer Research Fund are to join together as Cancer Research UK. The merger, due to take effect in early February 2002, will have an annual R&D budget of £130 million ($186 million), making it the "biggest independent cancer research organisation in the world", say the charities. With a "shared vision to conquer cancer through world class research", they aim to combine their complementary strengths to "push through new and effective treatments faster than ever before". Imperial Cancer is considered to be at the forefront of exploratory science, while the CRC is described as Europe`s leader in anti-cancer drug development. The Medical Research Council (MRC) has welcomed the news. Professor Sir George Radda, MRC chief executive and current chair of the National Cancer Research Institute, billed it a "new era in cancer research".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel